• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Ahmedabad, May 15

Cadila Healthcare Ltd (Zydus Cadila) has received four product approvals from the US Food and Drug Administration to market Pravastatin sodium tablets 10, 20, 40 and 80 mg and tentative approvals for EscitalopramOxalate tablets, 5,10 and 20 mg, Losartan potassium and Hydrochlorthiazide tablets 50 mg/12.5 mg and 100 mg/25 mg and Anastrazole tablets 1 mg, according to a release here today. The US market of Pravastatin sodium tablets, a lipid lowering agent which falls in the cardiovascular segment, was estimated at $1.9 billion in 2007, while the branded sales of Escitalopram Oxalate tablets, an anti-depressant, were estimated at $3 billion. Losartanpotassium and Hydrochlorthiazide tablets, an anti-hypertensive, were estimated at $ 785 million. Anastrazole, a hormone therapy to treat breast cancer, had a market worth $ 813million. —

Our Bureau

More Stories on : Announcements | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Cadila products get USFDA nod

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line